Shilpa Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SHILPA, and when can generic versions of SHILPA drugs launch?
SHILPA has thirteen approved drugs.
There are five US patents protecting SHILPA drugs. There are two tentative approvals on SHILPA drugs.
There are fifty-four patent family members on SHILPA drugs in twenty-six countries and forty-eight supplementary protection certificates in sixteen countries.
Summary for Shilpa
| International Patents: | 54 |
| US Patents: | 5 |
| Tradenames: | 11 |
| Ingredients: | 11 |
| NDAs: | 13 |
| Patent Litigation for Shilpa: | See patent lawsuits for Shilpa |
Drugs and US Patents for Shilpa
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shilpa | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 205934-001 | Dec 22, 2015 | AP | RX | Yes | Yes | 9,763,880 | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Shilpa | CAPECITABINE | capecitabine | TABLET;ORAL | 207456-001 | Dec 12, 2016 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Shilpa | APREMILAST | apremilast | TABLET;ORAL | 211774-002 | Apr 7, 2023 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Shilpa | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 205934-003 | Dec 22, 2015 | AP | RX | Yes | Yes | 8,940,786 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| Shilpa | GEMCITABINE HYDROCHLORIDE | gemcitabine hydrochloride | INJECTABLE;INJECTION | 210991-002 | Oct 4, 2019 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Shilpa Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2798180 | ⤷ Try a Trial |
| India | 2661DEN2015 | ⤷ Try a Trial |
| Japan | 2013525485 | ⤷ Try a Trial |
| Hong Kong | 1259184 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2011139899 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Shilpa Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0817775 | 5/2006 | Austria | ⤷ Try a Trial | PRODUCT NAME: ERLOTINIB UND SEINE PHARMAZEUTISCH ANNEHMBAREN SALZE, INSBESONDERE ERLOTINIBHYDROCHLORID; NAT. REGISTRATION NO/DATE: EU/1/05/311/001 - EU/1/05/311/003 20050919; FIRST REGISTRATION: CH 57266 01 - 57266 03 20050321 |
| 0122707 | 96C0030 | Belgium | ⤷ Try a Trial | PRODUCT NAME: CHLORHYDRATE DE GEMCITABINE EQUIVALENT EN GEMCITABINE; NAT. REGISTRATION NO/DATE: 58 IS 88 F 12 19960606; FIRST REGISTRATION: NL RVG 17854 19950327 |
| 0564409 | SPC/GB02/016 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: IMATINIB (INN I.E. NON INTELLECTUAL PROPRIETARY NAME) OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS, ESPECIALLY THE MONOMETHANESULFONATE SALT; REGISTERED: CH IKS-NR: 55807 20010621; UK SG(2001) D/292083 20011108 |
| 1746976 | 2017/029 | Ireland | ⤷ Try a Trial | PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT; REGISTRATION NO/DATE: EU/1/16/1130 20161014 |
| 2962690 | LUC00125 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: APREMILAST, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/14/981 20150116 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
